文献类型：期刊文献

英文题名：FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta-Analysis and Bioinformatics Analysis

作者：Zhang, Guangming[1,2,3,4];Wang, Yongfeng[1,2,3];Han, Xiaoyong[5];Lu, Tingting[4,6];Fu, Liangyin[1,2,3];Jin, Haojie[7];Yang, Kehu[4,8];Cai, Hui[1,2,3]

第一作者：Zhang, Guangming

通信作者：Cai, H[1];Cai, H[2];Cai, H[3];Yang, KH[4];Yang, KH[5]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, Dept Gen Surg Clin Med Ctr, Lanzhou, Peoples R China;[3]Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou, Peoples R China;[4]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China;[5]Ning Xia Med Univ, Yinchuan, Peoples R China;[6]Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou, Peoples R China;[7]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China;[8]Key Lab Evidence Based Med & Knowledge Translat Ga, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Dept Gen Surg Clin Med Ctr, Lanzhou, Peoples R China;[3]corresponding author), Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou, Peoples R China;[4]corresponding author), Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China;[5]corresponding author), Key Lab Evidence Based Med & Knowledge Translat Ga, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;

年份：2022

卷号：12

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-85133322915);WOS:【SCI-EXPANDED(收录号:WOS:000812953500001)】；

基金：This study was supported by The 2021 Central-Guided Local Science and Technology Development Fund (ZYYDDFFZZJ-1); Natural Science Foundation of Gansu Province, China (No. 18JR3RA052); Lanzhou Talent Innovation and Entrepreneurship Project Task Contract (No. 2016-RC-56); National Key Research and Development Program (No. 2018YFC1311506); Fundamental Research Funds for the Central Universities (No. 2020jbkyzx001; lzujbky-2020-kb20); Guiding plan for scientific and technological development of Lanzhou (No. 2019-ZD-102).

语种：英文

外文关键词：lncRNA; FOXP4-AS1; cancers; prognosis; meta-analysis; bioinformatics analysis

摘要：Background: Cancer is one of the leading causes of death worldwide. Early diagnosis can significantly lower cancer-related mortality. Studies have shown that the lncRNA Forkhead box P4 antisense RNA 1 (FOXP4-AS1) is aberrantly expressed in various solid tumors. A meta-analysis was performed to evaluate the correlation of FOXP4-AS1 with the prognosis of cancer patients and determine the clinical value of FOXP4-AS1 as a potential diagnostic marker. Methods: Correlational studies from the Web of Science, Embase, OVID, Cochrane and PubMed databases were screened (up to April 1, 2021). Meta-analysis was performed using Stata SE12.0 software. Results: Eleven original studies with 1,332 patients who were diagnosed with a solid cancer (nasopharyngeal carcinoma, hepatocellular carcinoma, colorectal cancer, gastric cancer, osteosarcoma, mantle cell lymphoma, prostate cancer, and pancreatic ductal adenocarcinoma) were included in the meta-analysis. High expression of FOXP4-AS1 was correlated with poor overall survival (OS) (HR = 1.77, 95% CI 1.29-2.44, P < 0.001) and shorter disease-free survival (DFS) (HR = 1.66, 95% CI 1.01-2.72, P = 0.044). Subgroup analysis based on sample size, follow-up time and Newcastle-Ottawa Scale (NOS) score revealed significant differences between FOXP4-AS1 levels and OS (P < 0.05). However, the expression level of FOXP4-AS1 was not significantly correlated with the OS of gastric cancer patients (P = 0.381). High expression of FOXP4-AS1 was predictive of a larger tumor size (OR = 3.82, 95% CI 2.3-6.3, P < 0.001). Conclusions: Overexpression of FOXP4-AS1 correlates with poor prognosis of cancer patients, and is a potential prognostic biomarker and therapeutic target.